Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RARE

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the efficacy of its drug setrusumab for treating Osteogenesis Imperfecta [1][1][1] Summary by Relevant Sections Class Action Details - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, can seek to be lead plaintiffs in the class action lawsuit, which is titled Bailey v. Ultragenyx Pharmaceutical Inc. [1][1] - The lawsuit alleges that Ultragenyx and its executives made false statements about the reliability of data from the Phase III Orbit study, which was intended to show the drug's effectiveness [1][1] Allegations Against Ultragenyx - The lawsuit claims that Ultragenyx created a misleading impression of having reliable information regarding the effects of setrusumab while downplaying the risks associated with the Phase III Orbit study [1][1] - It is alleged that the company failed to disclose that the Phase II results lacked a placebo control group, which could have influenced the perceived effectiveness of the treatment [1][1] Stock Price Impact - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by more than 25% [1][1] - On December 29, 2025, after revealing that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, the stock price dropped by over 42% [1][1] Legal Process for Lead Plaintiffs - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Ultragenyx common stock during the class period to seek appointment as lead plaintiff, representing the interests of all class members [1][1] - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [1][1] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1][1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [1][1]